Insulin aspart, recombinant Subcutaneous and Rituxan Hycela
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Rituxan Hycela and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: hyaluronidase / rituximab
Brand name: Rituxan Hycela
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Rituximab
- Insulin aspart, recombinant Subcutaneous-Rituximab and Hyaluronidase
- Insulin aspart, recombinant Subcutaneous-Rituximab and hyaluronidase human, recombinant Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Rituximab Intravenous
- Insulin aspart, recombinant Subcutaneous-Riva-Amoxicillin
- Insulin aspart, recombinant Subcutaneous-Rivaroxaban
- Rituxan Hycela-Insulin degludec
- Rituxan Hycela-Insulin Degludec (U-100) Prefilled Pens
- Rituxan Hycela-Insulin Degludec (U-100) Vials
- Rituxan Hycela-Insulin Degludec (U-200) Prefilled Pens
- Rituxan Hycela-Insulin degludec and liraglutide
- Rituxan Hycela-Insulin degludec and liraglutide Subcutaneous